

# Solventum at a Glance

At Solventum, we enable better, smarter, safer healthcare to improve lives. Across our businesses – Medical Surgical (MedSurg), Dental Solutions, Health Information Services (HIS) and Purification & Filtration (P&F) – we have strong positions in diverse and growing markets, trusted and recognized brands, and global commercial scale and reach.



 **70+**  
year history of innovation

 **20,000+**  
employees<sup>1</sup>

 **6,500+**  
patents issued<sup>1</sup>

 **100,000+**  
customers and channel partners globally in 90+ countries

## Business Segments at a Glance

|  | Total Company Sales <sup>2</sup> | Growth Drivers   | Q3 2025 Highlights  |
|--|----------------------------------|--|---|
| <p><b>MedSurg</b></p> <p>Provides advanced wound care, infection prevention and surgical supplies that are intended to accelerate healing, prevent complications and lower the total cost of care globally</p>      | <b>58%</b>                       | <ul style="list-style-type: none"> <li>Negative Pressure Wound Therapy</li> <li>I.V. Site Management</li> <li>Sterilization Assurance</li> </ul>   | <ul style="list-style-type: none"> <li>Specialized commercial organization delivering results</li> <li>Negative Pressure Wound Therapy growth</li> <li>Upselling and new product launches in Infection Prevention and Surgical Solutions</li> </ul>   |
| <p><b>Dental Solutions</b></p> <p>Offers the most comprehensive dental solutions for patients to enjoy healthy, beautiful smiles through game-changing innovation</p>   | <b>16%</b>                       | <ul style="list-style-type: none"> <li>Core Restoratives</li> </ul>  | <ul style="list-style-type: none"> <li>Introduced refined and redesigned Clarity™ brand</li> <li>Launched Filtek™ composite warmer, the first fully Solventum-branded restorative device</li> <li>Backorder and service level improvements</li> </ul> |
| <p><b>Health Information Systems</b></p> <p>Delivers innovative software solutions and services, designed to eliminate revenue cycle waste, create more time to care and support the shift to value-based care</p>  | <b>16%</b>                       | <ul style="list-style-type: none"> <li>Revenue Cycle Management</li> </ul>   | <ul style="list-style-type: none"> <li>Strong growth in revenue cycle management</li> <li>Expanded adoption of 360 Encompass™</li> <li>Progress in autonomous coding with customers and partners</li> </ul>   |
| <p><b>Purification &amp; Filtration</b></p> <p>Filters and membranes for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics and food and beverage products</p>                |                                  | <ul style="list-style-type: none"> <li>Announced the sale of the Purification &amp; Filtration business to Thermo Fisher Scientific on Feb. 25, 2025</li> <li>Amended the transaction for Solventum to retain the drinking water filtration business on June 25, 2025</li> <li>Closed sale transaction with Thermo Fisher Scientific on Sept. 1, 2025</li> </ul> |   |

1. Employees and patents issued excludes P&F segment  
 2. Calculated as % of Q3 2025 net sales

# Q3 Financial Highlights\*

## Sales

**\$2.1B** +0.7% total sales growth  
+2.7% organic sales growth

## Diluted GAAP EPS

**\$7.22**

Six consecutive quarters of positive sales volume growth

\* See non-GAAP financial measures and reconciliation schedules included in our Earnings Release dated November 6, 2025, which can be found on our investor relations website.

## Operating Cash Flow

**\$75M**

## Diluted Adjusted EPS

**\$1.50**

## Segment Highlights

Strong Progress Propelled by Growth Drivers

| Business Segment           | Reported Sales Growth | Organic Sales Growth |
|----------------------------|-----------------------|----------------------|
| MedSurg                    | +2.1%                 | +1.1%                |
| Dental Solutions           | +8.4%                 | +6.5%                |
| Health Information Systems | +5.9%                 | +5.6%                |
| Purification & Filtration  | -28.7%                | +6.4%                |

## Updated 2025 Guidance

Reflects Solid Momentum<sup>3</sup>

### Organic Sales Growth

increasing to high-end of the range

**+2.0% to +3.0%**

### Adjusted EPS

**\$5.98 to \$6.08**

(compared to prior range of \$5.88 to \$6.03)

### Free Cash Flow

**\$150M to \$250M**

(Reduced from \$450M to \$550M due to P&F divestiture impact)

3. Note: Full year 2025 guidance includes results of the P&F segment for the period we owned the business. The sale transaction closed on September 1, 2025



### Forward-Looking Statements

This communication and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning. All statements that reflect Solventum's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding Solventum's strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances. Actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. Solventum assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the SEC. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

### Non-GAAP Financial Measures

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash. Refer to the reconciliation schedules included in our Earnings Release dated November 6, 2025, which can be found on our investor relations website, for descriptions and reconciliations of financial measures such as organic sales growth, adjusted operating income and adjusted operating income margin, adjusted earnings per share, and free cash flow. Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted earnings per share, and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP.

The Q3 2025 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum's website: [investors.solventum.com](https://investors.solventum.com).